ABVC vs DVA · rev $509.6K vs P/E 14, rev $12.82B
ABVC Biopharma Inc (ABVC) versus DaVita HealthCare Partners Inc (DVA) — a side-by-side from cached financials, not a winner call.
ABVC Biopharma Inc (ABVC) is a biotechnology company listed on NASDAQ.
DaVita HealthCare Partners Inc (DVA) is a medical care facilities company listed on US.
Latest reported ABVC revenue for 2024-12-31 was $509.6K. Net income was -$5.3M. Revenue was up 234.3% from 2023-12-31 to 2024-12-31. ABVC currently screens at market cap $35.9M.
Latest reported DVA revenue for 2024-12-31 was $12.82B. Net income was $1.25B. Revenue was up 5.6% from 2023-12-31 to 2024-12-31. DVA currently screens at market cap $10.77B and trailing P/E 14.1.
ABVC currently screens at market cap $35.9M. DVA currently screens at market cap $10.77B and trailing P/E 14.1.
Not investment advice. Open the ABVC and DVA stock pages for the full models.
Not investment advice.